Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Feed not found.
Contact us
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st fl.), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
D-U-N-S: 362071645
-
- + 7 985 908 58 18 9am-6pm GMT+3
-
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- U.S. FDA Approves Subcutaneous Administration of Takeda's Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
- FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
- FDA Approves Ryzumvi (phentolamine) Ophthalmic Solution for the Treatment of Pharmacologically-Induced Mydriasis
- FDA Approves Likmez (metronidazole) Oral Suspension for the Treatment of Parasitic and Anaerobic Bacterial Infections
- US FDA Approves Jardiance for the Treatment of Adults with Chronic Kidney Disease
News and press releases
- EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep, CHMP, 15/09/2023
- Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies, , 15/09/2023
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023, CHMP, 15/09/2023
- EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna, CHMP, 15/09/2023
Drugs.com - Clinical Trials
- NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26...
- Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia CUPERTINO, Calif., Sept. 25,...
- Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial 22 September 2023 --...
- Clinical Trial to Test Immune Modulation Strategy for Hospitalized Covid-19 Patients Begins September 22, 2023 -- A...